JP2012510431A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012510431A5 JP2012510431A5 JP2011537796A JP2011537796A JP2012510431A5 JP 2012510431 A5 JP2012510431 A5 JP 2012510431A5 JP 2011537796 A JP2011537796 A JP 2011537796A JP 2011537796 A JP2011537796 A JP 2011537796A JP 2012510431 A5 JP2012510431 A5 JP 2012510431A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- composition
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 45
- 239000012634 fragment Substances 0.000 claims 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims 15
- 102000040430 polynucleotide Human genes 0.000 claims 14
- 108091033319 polynucleotide Proteins 0.000 claims 14
- 239000002157 polynucleotide Substances 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- 229960005486 vaccine Drugs 0.000 claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 8
- 208000015943 Coeliac disease Diseases 0.000 claims 6
- 108010068370 Glutens Proteins 0.000 claims 6
- 235000021312 gluten Nutrition 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 230000028327 secretion Effects 0.000 claims 4
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical group OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000003814 Interleukin-10 Human genes 0.000 claims 2
- 108090000174 Interleukin-10 Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Chemical group OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Chemical group OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims 2
- 125000003368 amide group Chemical group 0.000 claims 2
- 230000030741 antigen processing and presentation Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 235000013305 food Nutrition 0.000 claims 2
- 230000006058 immune tolerance Effects 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 229940076144 interleukin-10 Drugs 0.000 claims 2
- 230000002797 proteolythic effect Effects 0.000 claims 2
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 150000001408 amides Chemical group 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11864308P | 2008-11-30 | 2008-11-30 | |
| US61/118,643 | 2008-11-30 | ||
| PCT/AU2009/001556 WO2010060155A1 (en) | 2008-11-30 | 2009-11-30 | Compositions and methods for treatment of celiac disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015235197A Division JP6027215B2 (ja) | 2008-11-30 | 2015-12-01 | セリアック病の処置のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012510431A JP2012510431A (ja) | 2012-05-10 |
| JP2012510431A5 true JP2012510431A5 (enExample) | 2013-03-28 |
| JP5851243B2 JP5851243B2 (ja) | 2016-02-03 |
Family
ID=42225141
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011537796A Expired - Fee Related JP5851243B2 (ja) | 2008-11-30 | 2009-11-30 | セリアック病の処置のための組成物および方法 |
| JP2015235197A Expired - Fee Related JP6027215B2 (ja) | 2008-11-30 | 2015-12-01 | セリアック病の処置のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015235197A Expired - Fee Related JP6027215B2 (ja) | 2008-11-30 | 2015-12-01 | セリアック病の処置のための組成物および方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US8835603B2 (enExample) |
| EP (3) | EP2977053B1 (enExample) |
| JP (2) | JP5851243B2 (enExample) |
| CN (2) | CN102438643B (enExample) |
| AU (1) | AU2009321481B2 (enExample) |
| BR (1) | BRPI0922122A2 (enExample) |
| CA (2) | CA3042826A1 (enExample) |
| DK (2) | DK2367561T3 (enExample) |
| ES (2) | ES2642096T3 (enExample) |
| HK (1) | HK1249446A1 (enExample) |
| HR (1) | HRP20150873T1 (enExample) |
| HU (1) | HUE027237T2 (enExample) |
| MX (1) | MX346450B (enExample) |
| NZ (1) | NZ593474A (enExample) |
| PT (1) | PT2367561E (enExample) |
| WO (1) | WO2010060155A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0212885D0 (en) | 2002-06-05 | 2002-07-17 | Isis Innovation | Therapeutic epitopes and uses thereof |
| US10105437B2 (en) | 2004-04-28 | 2018-10-23 | Btg International Limited | Epitopes related to coeliac disease |
| EP1755639B1 (en) | 2004-04-28 | 2017-08-16 | BTG International Limited | Epitopes related to coeliac disease |
| PT2367561E (pt) | 2008-11-30 | 2015-10-23 | Immusant Inc | Composições e métodos para o tratamento da doença celíaca |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| CN108129554A (zh) | 2010-08-10 | 2018-06-08 | 洛桑聚合联合学院 | 红细胞结合性治疗剂 |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| MX374971B (es) * | 2011-01-20 | 2025-03-06 | Cyrex Laboratories Llc | Metodos y aparato para la deteccion de sensibilidad al gluten y su diferenciacion de la enfermedad celiaca |
| ITRM20110487A1 (it) * | 2011-09-19 | 2013-03-20 | Consiglio Per La Ricerca E La Speri Mentazione In | Peptidi aventi effetto protettivo nei confronti della attività infiammatoria del peptide 31-43 della a-gliadina nella malattia celiaca. |
| ES2402286B1 (es) * | 2011-09-29 | 2014-03-04 | Universidad De Valladolid | Péptido inmunogénico del gluten y sus aplicaciones. |
| CA2864080C (en) | 2012-02-07 | 2023-04-25 | Vibrant Holdings, Llc | Substrates, peptide arrays, and methods |
| KR20220166879A (ko) | 2012-06-21 | 2022-12-19 | 노쓰웨스턴유니버시티 | 펩티드 접합된 입자 |
| US10006909B2 (en) | 2012-09-28 | 2018-06-26 | Vibrant Holdings, Llc | Methods, systems, and arrays for biomolecular analysis |
| US10286376B2 (en) | 2012-11-14 | 2019-05-14 | Vibrant Holdings, Llc | Substrates, systems, and methods for array synthesis and biomolecular analysis |
| US11439594B2 (en) | 2012-12-04 | 2022-09-13 | Phosphorex, Inc. | Microparticles and nanoparticles having negative surface charges |
| KR20250076678A (ko) | 2013-03-13 | 2025-05-29 | 코어 파마슈티칼스 디벨롭먼트 컴퍼니 인크. | 염증 치료용 면역-변형된 입자 |
| US20160041148A1 (en) * | 2013-03-14 | 2016-02-11 | Immusant,Inc. | Placebo-controlled gluten challenge method |
| WO2014182897A2 (en) * | 2013-05-08 | 2014-11-13 | Jm Biologicals | Compositions and methods for the production of gluten free food products |
| HRP20192270T4 (hr) | 2013-08-13 | 2024-03-01 | Northwestern University | Konjugirane čestice peptida |
| WO2015038624A1 (en) * | 2013-09-10 | 2015-03-19 | Immusant, Inc. | Dosage of a gluten peptide composition |
| US20160238590A1 (en) * | 2013-09-20 | 2016-08-18 | Immusant, Inc. | Compositions and methods related to oat sensitivity |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| SG10202010936RA (en) | 2014-02-21 | 2020-12-30 | Ecole Polytecnique Fed De Lausanne Epfl Epfl Tto | Glycotargeting therapeutics |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| CA2946887A1 (en) * | 2014-04-24 | 2015-10-29 | Immusant, Inc. | Compositions comprising gluten peptides and uses thereof |
| WO2016040703A1 (en) * | 2014-09-10 | 2016-03-17 | Vibrant Holdings, Llc | Peptide microarrays and novel biomarkers for celiac disease |
| CA2962933A1 (en) | 2014-09-29 | 2016-04-07 | Immusant, Inc. | Use of hla genetic status to assess or select treatment of celiac disease |
| AU2015349728A1 (en) * | 2014-11-21 | 2017-07-13 | Immusant, Inc. | Peptides for use in treatment and diagnosis of type 1 diabetes |
| KR101736744B1 (ko) | 2014-12-03 | 2017-05-17 | 주식회사 한국유전자정보연구원 | 셀리악병 진단용 프라이머 세트와 이를 이용한 셀리악병 진단방법 |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| WO2017058074A1 (en) * | 2015-08-30 | 2017-04-06 | Diamyd Medical Ab | Combination therapy using gliadin and gamma aminobutyric acid |
| AU2016379413B2 (en) | 2015-12-23 | 2024-04-04 | Cour Pharmaceuticals Development Company Inc. | Covalent polymer-antigen conjugated particles |
| EP3416624B8 (en) | 2016-02-18 | 2023-08-23 | Cour Pharmaceuticals Development Company Inc. | Process for the preparation of tolerizing immune-modulating particles |
| EP3464322B1 (en) * | 2016-06-05 | 2023-04-05 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Novel molecules for the treatment of inflammation |
| WO2018005700A1 (en) | 2016-06-28 | 2018-01-04 | Immusant, Inc. | Escalating dosage schedules for treating celiac disease |
| RU2763311C2 (ru) | 2017-01-12 | 2021-12-28 | Проби Аб | Пробиотические композиции и их применение |
| WO2018218250A2 (en) | 2017-05-26 | 2018-11-29 | Vibrant Holdings, Llc | Photoactive compounds and methods for biomolecule detection and sequencing |
| EP3638296A1 (en) | 2017-06-16 | 2020-04-22 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
| CA3074839A1 (en) | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof |
| BR112020008513A2 (pt) * | 2017-10-30 | 2020-10-20 | Immusant, Inc. | regimes de dosagem para a doença celíaca |
| JP6568193B2 (ja) | 2017-12-19 | 2019-08-28 | ホーユー株式会社 | エピトープ |
| EP3749285A4 (en) * | 2018-02-08 | 2022-02-23 | Cour Pharmaceuticals Development Company Inc. | TREATMENT OF CELIAC DISEASE WITH TOLERABLE PARTICLES |
| CN112384239A (zh) | 2018-05-09 | 2021-02-19 | 芝加哥大学 | 影响免疫耐受的组合物和方法 |
| JP7422087B2 (ja) | 2018-05-09 | 2024-01-25 | ヴィブラント ホールディングス リミテッド ライアビリティ カンパニー | 光活性化された作用物質を使用してポリヌクレオチドアレイを合成する方法 |
| CN113227124B (zh) * | 2018-10-31 | 2025-04-08 | 味之素株式会社 | 具有针对抗体的亲和性物质、切割性部分及反应性基团的化合物或其盐 |
| WO2020181272A1 (en) * | 2019-03-06 | 2020-09-10 | Cue Biopharma, Inc. | Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof |
| US20230001010A1 (en) * | 2019-07-19 | 2023-01-05 | The Regents Of The University Of Michigan | Compositions and methods for treating autoimmune disorders |
| JP7374687B2 (ja) * | 2019-09-26 | 2023-11-07 | 三和酒類株式会社 | ペンタペプチド化合物 |
| EP4061403A4 (en) * | 2019-11-19 | 2023-12-27 | Spark Therapeutics, Inc. | SECRETABLE PROTEIN-INDUCED IMMUNE TOLERANCE AND TREATMENT OF AUTOIMMUNE, ALLERGIC AND OTHER DISEASES AND DISORDERS |
| EP4323768A1 (en) | 2021-04-16 | 2024-02-21 | Cour Pharmaceuticals Development Company Inc. | Method of tracking maintenance of immunological tolerance |
| JP2025526212A (ja) | 2022-07-21 | 2025-08-13 | アンティバ バイオサイエンシズ インコーポレイテッド | Ｈｐｖ感染症及びｈｐｖ誘発性新生物の治療用の組成物及び剤形 |
| WO2024168151A2 (en) * | 2023-02-09 | 2024-08-15 | The Board Of Trustees Of The Leland Stanford Junior University | Capped peptides and methods for using the same |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4740371A (en) | 1984-09-17 | 1988-04-26 | International Institute Of Cellular And Molecular Pathology | Treatment of allergy |
| DE3779909T2 (de) | 1986-03-06 | 1993-01-07 | Commw Scient Ind Res Org | In-vitro-testverfahren zum nachweis zellulaerer immunresponsen. |
| FR2615622B1 (fr) | 1987-05-19 | 1994-05-06 | Ire Medgenix Sa | Dosage plasmatique de monokines |
| US5547669A (en) | 1989-11-03 | 1996-08-20 | Immulogic Pharma Corp | Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I |
| US5674978A (en) | 1990-09-21 | 1997-10-07 | The Regents Of The University Of California | Peptides derived from glutamic acid decarboxylase |
| US5998366A (en) | 1990-09-21 | 1999-12-07 | The Regents Of The University Of California | Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders |
| IL105153A (en) | 1992-03-25 | 1999-12-22 | Immulogic Pharma Corp | Therapeutic compositions comprising peptides derived from human t cell reactive feline protein |
| US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
| WO1996006630A1 (en) | 1994-08-26 | 1996-03-07 | The Regents Of The University Of California | Methods and compositions for modulating a t cell response |
| US6759234B1 (en) | 1994-09-02 | 2004-07-06 | Immulogic Pharmaceutical Corporation | Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response |
| AU7726094A (en) | 1994-09-02 | 1996-03-27 | Immulogic Pharmaceutical Corporation | Peptide compositions capable of down regulating an antigen specific immune response |
| US5750356A (en) | 1996-05-31 | 1998-05-12 | Anergen, Inc. | Method for monitoring T cell reactivity |
| EP0905518A1 (en) | 1997-09-23 | 1999-03-31 | Academisch Ziekenhuis Leiden | Peptides specific for gluten-sensitive T-cells and use thereof |
| US6300308B1 (en) | 1997-12-31 | 2001-10-09 | Board Of Regents, The University Of Texas System | Methods and compositions for inducing autoimmunity in the treatment of cancers |
| GB9923306D0 (en) | 1999-10-01 | 1999-12-08 | Isis Innovation | Diagnostic and therapeutic epitope, and transgenic plant |
| US6667160B2 (en) | 2000-03-15 | 2003-12-23 | Kenneth D. Fine | Method for diagnosing immunologic food sensitivity |
| US8110218B2 (en) | 2000-11-30 | 2012-02-07 | The Research Foundation Of State University Of New York | Compositions and methods for less immunogenic protein-lipid complexes |
| EP1241476A1 (en) | 2001-03-12 | 2002-09-18 | Mabtech AB | Diagnosis of metal allergy through cytokine release by T-cells in vitro |
| CA2440474A1 (en) | 2001-04-05 | 2002-10-17 | Virginia Mason Research Center | Methods of mhc class ii epitope mapping, detection of autoimmune t cells and antigens, and autoimmune treatment |
| MXPA03009313A (es) | 2001-04-12 | 2004-11-12 | Academish Ziekenhuis Leiden | Metodos y medios para uso de receptores de celulas t restringidos por hla-dq y peptidos derivados de prolamina unidos a hla-dq. |
| FI20010868A0 (fi) | 2001-04-25 | 2001-04-25 | Markku Maeki | Menetelmä ja välineet gluteenin indusoimien tautien havaitsemiseksi |
| ATE414534T1 (de) | 2001-12-05 | 2008-12-15 | Circassia Ltd | Immunotherapeutische methoden und systeme |
| EP1332760A1 (en) | 2002-02-04 | 2003-08-06 | Academisch Ziekenhuis Leiden | Novel epitopes for celiac disease and autoimmune diseases, methods for detecting those and novel non-antigenic food compounds |
| EP1572127B2 (en) | 2002-02-14 | 2014-10-29 | The Board of Trustees of the Leland Stanford Junior University | Enzyme treatment of foodstuffs for celiac sprue |
| US7320788B2 (en) | 2002-02-14 | 2008-01-22 | The Board Of Trustees Of The Leland Stanford Junior University | Enzyme treatment of foodstuffs for Celiac Sprue |
| AU2003234634A1 (en) | 2002-05-14 | 2003-12-02 | Felix Hausch | Drug therapy for celiac sprue |
| US7462688B2 (en) | 2002-05-14 | 2008-12-09 | The Board Of Trustees Of The Leland Stanford Junior University | Peptides for diagnostic and therapeutic methods for celiac sprue |
| US7202216B2 (en) | 2002-05-14 | 2007-04-10 | The Board Of Trustees Of The Leland Stanford Junior University | Drug therapy for celiac sprue |
| GB0212885D0 (en) | 2002-06-05 | 2002-07-17 | Isis Innovation | Therapeutic epitopes and uses thereof |
| AU2002952834A0 (en) | 2002-09-16 | 2002-12-05 | The Walter And Eliza Hall Institute Of Medical Research | A method of treating an autoimmune disease |
| AU2003277989B2 (en) | 2002-11-08 | 2010-04-22 | QIAGEN Australia Holding Pty. Ltd. | Diagnostic assay for measuring a cell mediated immune response |
| AU2002952548A0 (en) | 2002-11-08 | 2002-11-21 | Cellestis Limited | Diagnostic assay |
| AU2003294473A1 (en) | 2002-11-20 | 2004-06-15 | The Board Of Trustees Of The Leland Stanford Junior University | Diagnostic method for celiac sprue |
| US7563864B2 (en) * | 2004-04-26 | 2009-07-21 | Celiac Sprue Research Foundation | Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten |
| EP1755639B1 (en) * | 2004-04-28 | 2017-08-16 | BTG International Limited | Epitopes related to coeliac disease |
| GB0409775D0 (en) | 2004-04-30 | 2004-06-09 | Mabtech Ab | Assay |
| EP1812563B1 (en) | 2004-10-29 | 2013-04-10 | Benaroya Research Institute at Virginia Mason | Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use |
| WO2007022477A2 (en) | 2005-08-17 | 2007-02-22 | Multicell Immunotherapeutics, Inc. | Methods and compositions to generate and control the effector profile of t cells |
| US20090304754A1 (en) | 2005-10-12 | 2009-12-10 | Srebrenka Robic | Pegylated glutenase polypeptides |
| CA2649296A1 (en) | 2006-04-13 | 2007-10-25 | Peptimmune, Inc. | Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability |
| WO2008090223A2 (en) * | 2007-01-25 | 2008-07-31 | Actogenix N.V. | Treatment of immune disease by mucosal delivery of antigens using genetically modified lactobacillus |
| ITFE20070003A1 (it) | 2007-02-01 | 2007-05-03 | Girolamo Calo' | Utilizzo di peptidi ricchi in prolina e glutamina capaci di legarsi alle molecole hla-dq2 e dq8 come "carriers specifici" di agenti capaci di danneggiare o uccidere le cellule che esprimono dette molecole hla nel contesto dell a mucosa enterica di pa |
| US8871508B2 (en) | 2007-03-16 | 2014-10-28 | Cellestis Limited | Cell-mediated immune response assay and kits therefor |
| US20090311727A1 (en) | 2008-04-21 | 2009-12-17 | Bio-Rad Laboratories, Inc. | Recombinant deamidated gliadin antigen |
| EP2277046A2 (en) | 2008-05-16 | 2011-01-26 | The Board of Trustees of The Leland Stanford Junior University | Non-inflammatory gluten peptide analogues as biomarkers for celiac sprue |
| CA2731854C (en) | 2008-07-25 | 2020-06-30 | Cellestis Limited | Measurement of cell-mediated immune response reactivity to detect or monitor a disease or condition |
| PT2367561E (pt) | 2008-11-30 | 2015-10-23 | Immusant Inc | Composições e métodos para o tratamento da doença celíaca |
| WO2011000773A1 (en) | 2009-07-02 | 2011-01-06 | Dsm Ip Assets B.V. | Testing efficacy for celiac disease |
| WO2011075773A1 (en) | 2009-12-23 | 2011-06-30 | Cellestis Limited | An assay for measuring cell-mediated immunoresponsiveness |
| WO2011146968A1 (en) | 2010-05-28 | 2011-12-01 | Cellestis Limited | A diagnostic assay |
| US20110311536A1 (en) | 2010-06-11 | 2011-12-22 | Dana-Farber Cancer Institute, Inc. | Prevention of type 1 diabetes by treg vaccination with an insulin mimetope |
| US9983207B2 (en) | 2011-06-29 | 2018-05-29 | Cellestis Limited | Cell mediated immune response assay with enhanced sensitivity |
| US20140248251A1 (en) | 2011-07-25 | 2014-09-04 | Daniel C. Adelman | Methods and Pharmaceutical Compositions for Treating Celiac Disease and Gluten Intolerance |
| US20130058970A1 (en) | 2011-09-06 | 2013-03-07 | Selecta Biosciences, Inc. | Induced tolerogenic dendritic cells to reduce systemic inflammatory cytokines |
| ES2402286B1 (es) | 2011-09-29 | 2014-03-04 | Universidad De Valladolid | Péptido inmunogénico del gluten y sus aplicaciones. |
| AU2012348122B2 (en) | 2011-12-05 | 2017-09-14 | Bio-Rad Laboratories, Inc. | Recombinant deamidated gliadin antigen |
| US20160041148A1 (en) | 2013-03-14 | 2016-02-11 | Immusant,Inc. | Placebo-controlled gluten challenge method |
| WO2015038624A1 (en) | 2013-09-10 | 2015-03-19 | Immusant, Inc. | Dosage of a gluten peptide composition |
| US20160238590A1 (en) | 2013-09-20 | 2016-08-18 | Immusant, Inc. | Compositions and methods related to oat sensitivity |
| CA2946887A1 (en) | 2014-04-24 | 2015-10-29 | Immusant, Inc. | Compositions comprising gluten peptides and uses thereof |
-
2009
- 2009-11-30 PT PT98284532T patent/PT2367561E/pt unknown
- 2009-11-30 CN CN200980155615.9A patent/CN102438643B/zh not_active Expired - Fee Related
- 2009-11-30 BR BRPI0922122A patent/BRPI0922122A2/pt not_active IP Right Cessation
- 2009-11-30 ES ES15168279.6T patent/ES2642096T3/es active Active
- 2009-11-30 DK DK09828453.2T patent/DK2367561T3/en active
- 2009-11-30 MX MX2011005632A patent/MX346450B/es active IP Right Grant
- 2009-11-30 HR HRP20150873TT patent/HRP20150873T1/hr unknown
- 2009-11-30 AU AU2009321481A patent/AU2009321481B2/en not_active Ceased
- 2009-11-30 EP EP15168279.6A patent/EP2977053B1/en not_active Not-in-force
- 2009-11-30 JP JP2011537796A patent/JP5851243B2/ja not_active Expired - Fee Related
- 2009-11-30 EP EP20090828453 patent/EP2367561B1/en not_active Not-in-force
- 2009-11-30 US US13/131,787 patent/US8835603B2/en active Active
- 2009-11-30 CN CN201510292861.6A patent/CN105079781B/zh not_active Expired - Fee Related
- 2009-11-30 HU HUE09828453A patent/HUE027237T2/en unknown
- 2009-11-30 NZ NZ593474A patent/NZ593474A/xx not_active IP Right Cessation
- 2009-11-30 WO PCT/AU2009/001556 patent/WO2010060155A1/en not_active Ceased
- 2009-11-30 EP EP17175226.4A patent/EP3269379A1/en not_active Withdrawn
- 2009-11-30 ES ES09828453.2T patent/ES2549481T3/es active Active
- 2009-11-30 CA CA3042826A patent/CA3042826A1/en not_active Abandoned
- 2009-11-30 CA CA2744787A patent/CA2744787C/en active Active
- 2009-11-30 DK DK15168279.6T patent/DK2977053T3/en active
-
2014
- 2014-08-13 US US14/459,060 patent/US9464120B2/en not_active Expired - Fee Related
-
2015
- 2015-12-01 JP JP2015235197A patent/JP6027215B2/ja not_active Expired - Fee Related
-
2016
- 2016-09-09 US US15/260,990 patent/US20170158743A1/en not_active Abandoned
-
2018
- 2018-06-18 US US16/010,596 patent/US20190048047A1/en not_active Abandoned
- 2018-07-16 HK HK18109154.3A patent/HK1249446A1/en unknown
-
2020
- 2020-05-27 US US16/884,533 patent/US20210115096A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012510431A5 (enExample) | ||
| HRP20150873T1 (hr) | Pripravci i postupci za lijeäśenje celijakije | |
| JP2021119174A (ja) | 子宮頸癌を処置する方法 | |
| JP7102430B2 (ja) | 糖尿病の治療のためのペプチド及び方法 | |
| JP2013517783A5 (enExample) | ||
| US9555086B2 (en) | Compositions and methods for inducing an immune response | |
| JP2013521789A5 (enExample) | ||
| JP2006187292A5 (enExample) | ||
| KR20170008873A (ko) | B형 간염 바이러스 감염에 대한 치료 백신접종을 위한 합성 롱 펩티드(slp) | |
| RU2011138160A (ru) | Пептиды foxmi и вакцины, содержащие их | |
| JP2011524737A5 (enExample) | ||
| RU2008109015A (ru) | Глипикан-3 (gpc3)-производные антигенные пептиды, отторгающие опухоли, используемые для нla-a2-положительных пациентов, и фармацевтическая продукция, включающая их | |
| JP2011522777A5 (enExample) | ||
| AU2011340430A1 (en) | Immune restricted peptides with increased efficacy | |
| JP2013523084A5 (enExample) | ||
| US20230054958A1 (en) | Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof | |
| NZ562436A (en) | Toll-like receptor 14 (TLR14) and use thereof | |
| CN102353794B (zh) | 筛选与鉴定幽门螺杆菌抗原表位肽的方法 | |
| JP2005524719A (ja) | 免疫応答を誘導するための方法および組成物 | |
| JP2012526519A5 (enExample) | ||
| RU2011140168A (ru) | Пептиды vangl1 и содержащие их вакцины | |
| AU2021265260A1 (en) | Methods of generating vaccines against novel coronavirus, named SARS-CoV-2 comprising variable epitope libraries (VELS) as immunogens | |
| US20100080817A1 (en) | HUMAN PAPILLOMAVIRUS / Ii-KEY HYBRIDS AND METHODS OF USE | |
| JP2014506114A5 (enExample) | ||
| TW201700495A (zh) | 辨識瀰漫性分支桿菌感染病人中抗丙型干擾素自體抗體之抗原決定區及其應用 |